How to read an FDA postmarket surveillance order

A postmarket surveillance order looks like enforcement the first time you see one, and it isn’t. FDA requiring a study after a device is already on the market doesn’t mean something went wrong — it means the agency decided, at clearance, at approval, or later, that a specific question about how the device performs over time still needed a real answer. Reading the order correctly starts with separating it from the things it resembles: a recall, a warning letter, a condition written into an approval.

What actually triggers one

FDA can attach a postmarket surveillance order at the moment of clearance or approval, tied to a specific unanswered question — how an implant performs at year eight, whether pediatric outcomes track what adult data predicted, whether a life-supporting device behaves the same way outside a monitored device user facility as it did in the pivotal study. The agency can also issue one later, if information surfacing after authorization raises a question that wasn’t obvious going in. Either way, the order is forward-looking by design: it asks for data that doesn’t exist yet, which is a different exercise than the passive adverse-event reporting every manufacturer already does through a medical device report.

What the order actually requires

The regulations at 21 CFR Part 822 put a clock on the response: a manufacturer under an active order has to submit a written surveillance plan for FDA’s review, spelling out the study design, the data sources, and the timeline for answering the question the order was built around. FDA can approve the plan or send it back for revision before any surveillance work formally counts toward the order. Once a plan is approved, the manufacturer executes it, files periodic progress reports on the schedule FDA sets, and continues until FDA terminates the order or the surveillance period specified in it runs out — the obligation has an end point, but it isn’t indefinite background paperwork either.

Most practitioners will go a full career without ever being handed a postmarket surveillance order directly — it applies to a narrow slice of devices by design. But recognizing one on sight, and knowing it’s a study commitment with real deadlines rather than an enforcement action to manage defensively, matters the moment a device you work on falls into that slice. It belongs in the same family as a recall or a medical device report: a downstream signal about how a device is actually performing, read correctly only once you know which mechanism produced it.